Review



huvec complete medium  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC huvec complete medium
    Huvec Complete Medium, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 3317 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/huvec complete medium/product/ATCC
    Average 99 stars, based on 3317 article reviews
    huvec complete medium - by Bioz Stars, 2026-03
    99/100 stars

    Images



    Similar Products

    huvec complete medium  (ATCC)
    99
    ATCC huvec complete medium
    Huvec Complete Medium, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/huvec complete medium/product/ATCC
    Average 99 stars, based on 1 article reviews
    huvec complete medium - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    complete huvec growth medium  (PromoCell)
    99
    PromoCell complete huvec growth medium
    Complete Huvec Growth Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/complete huvec growth medium/product/PromoCell
    Average 99 stars, based on 1 article reviews
    complete huvec growth medium - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    complete culture medium for huvec  (Procell Inc)
    90
    Procell Inc complete culture medium for huvec
    AEP inhibitor 7,8‐DHF <t>protect</t> <t>HUVECs</t> against oxygen–glucose deprivation by inhibiting tPA‐induced elevated LRP‐1, MMP2, and MMP9. HUVECs treated with 0.5 μM 7,8‐DHF for 24 h followed by OGD 4 h and reoxygen‐glucose plus tPA (500 ng/mL) for another 24 h as the methods part described. (A, B) Western blotting to evaluate the expression of ZO‐1, claudin5, occluding, and JAM‐1. (C) The viability of HUVECs at different time points. (D) AEP enzymatic analysis of HUVECs subjected to 24 h tPA treatment following 7,8‐DHF and OGD. (E, F) Western blotting to evaluate the expression of AEP, p‐TrkB, TrkB, LRP‐1, MMP2, and MMP9. (A) n = 4, (C) n = 6, (D) n = 4, (E) n = 4 per group. Data are presented as mean ± SEM, and statistical analysis is performed using one‐way ANOVA test followed by Tukey's multiple comparisons test when P value of Levene test > 0.05 or Welch test followed by Dunnett T3 multiple comparisons test when the P value of Levene test < 0.05. Normality and variance are assessed via Shapiro‐Wilk test and Levene's test, respectively. * P < 0.05, ** P < 0.01, *** P < 0.001.
    Complete Culture Medium For Huvec, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/complete culture medium for huvec/product/Procell Inc
    Average 90 stars, based on 1 article reviews
    complete culture medium for huvec - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    huvec specific complete medium  (Procell Inc)
    90
    Procell Inc huvec specific complete medium
    AEP inhibitor 7,8‐DHF <t>protect</t> <t>HUVECs</t> against oxygen–glucose deprivation by inhibiting tPA‐induced elevated LRP‐1, MMP2, and MMP9. HUVECs treated with 0.5 μM 7,8‐DHF for 24 h followed by OGD 4 h and reoxygen‐glucose plus tPA (500 ng/mL) for another 24 h as the methods part described. (A, B) Western blotting to evaluate the expression of ZO‐1, claudin5, occluding, and JAM‐1. (C) The viability of HUVECs at different time points. (D) AEP enzymatic analysis of HUVECs subjected to 24 h tPA treatment following 7,8‐DHF and OGD. (E, F) Western blotting to evaluate the expression of AEP, p‐TrkB, TrkB, LRP‐1, MMP2, and MMP9. (A) n = 4, (C) n = 6, (D) n = 4, (E) n = 4 per group. Data are presented as mean ± SEM, and statistical analysis is performed using one‐way ANOVA test followed by Tukey's multiple comparisons test when P value of Levene test > 0.05 or Welch test followed by Dunnett T3 multiple comparisons test when the P value of Levene test < 0.05. Normality and variance are assessed via Shapiro‐Wilk test and Levene's test, respectively. * P < 0.05, ** P < 0.01, *** P < 0.001.
    Huvec Specific Complete Medium, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/huvec specific complete medium/product/Procell Inc
    Average 90 stars, based on 1 article reviews
    huvec specific complete medium - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    complete medium of human umbilical vein endothelial cells (huvecs)  (Cyagen Biosciences)
    90
    Cyagen Biosciences complete medium of human umbilical vein endothelial cells (huvecs)
    AEP inhibitor 7,8‐DHF <t>protect</t> <t>HUVECs</t> against oxygen–glucose deprivation by inhibiting tPA‐induced elevated LRP‐1, MMP2, and MMP9. HUVECs treated with 0.5 μM 7,8‐DHF for 24 h followed by OGD 4 h and reoxygen‐glucose plus tPA (500 ng/mL) for another 24 h as the methods part described. (A, B) Western blotting to evaluate the expression of ZO‐1, claudin5, occluding, and JAM‐1. (C) The viability of HUVECs at different time points. (D) AEP enzymatic analysis of HUVECs subjected to 24 h tPA treatment following 7,8‐DHF and OGD. (E, F) Western blotting to evaluate the expression of AEP, p‐TrkB, TrkB, LRP‐1, MMP2, and MMP9. (A) n = 4, (C) n = 6, (D) n = 4, (E) n = 4 per group. Data are presented as mean ± SEM, and statistical analysis is performed using one‐way ANOVA test followed by Tukey's multiple comparisons test when P value of Levene test > 0.05 or Welch test followed by Dunnett T3 multiple comparisons test when the P value of Levene test < 0.05. Normality and variance are assessed via Shapiro‐Wilk test and Levene's test, respectively. * P < 0.05, ** P < 0.01, *** P < 0.001.
    Complete Medium Of Human Umbilical Vein Endothelial Cells (Huvecs), supplied by Cyagen Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/complete medium of human umbilical vein endothelial cells (huvecs)/product/Cyagen Biosciences
    Average 90 stars, based on 1 article reviews
    complete medium of human umbilical vein endothelial cells (huvecs) - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    complete huvec medium  (Corning Life Sciences)
    90
    Corning Life Sciences complete huvec medium
    AEP inhibitor 7,8‐DHF <t>protect</t> <t>HUVECs</t> against oxygen–glucose deprivation by inhibiting tPA‐induced elevated LRP‐1, MMP2, and MMP9. HUVECs treated with 0.5 μM 7,8‐DHF for 24 h followed by OGD 4 h and reoxygen‐glucose plus tPA (500 ng/mL) for another 24 h as the methods part described. (A, B) Western blotting to evaluate the expression of ZO‐1, claudin5, occluding, and JAM‐1. (C) The viability of HUVECs at different time points. (D) AEP enzymatic analysis of HUVECs subjected to 24 h tPA treatment following 7,8‐DHF and OGD. (E, F) Western blotting to evaluate the expression of AEP, p‐TrkB, TrkB, LRP‐1, MMP2, and MMP9. (A) n = 4, (C) n = 6, (D) n = 4, (E) n = 4 per group. Data are presented as mean ± SEM, and statistical analysis is performed using one‐way ANOVA test followed by Tukey's multiple comparisons test when P value of Levene test > 0.05 or Welch test followed by Dunnett T3 multiple comparisons test when the P value of Levene test < 0.05. Normality and variance are assessed via Shapiro‐Wilk test and Levene's test, respectively. * P < 0.05, ** P < 0.01, *** P < 0.001.
    Complete Huvec Medium, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/complete huvec medium/product/Corning Life Sciences
    Average 90 stars, based on 1 article reviews
    complete huvec medium - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    complete medium of huvecs (cat no. huvec-90011)  (Cyagen Biosciences)
    90
    Cyagen Biosciences complete medium of huvecs (cat no. huvec-90011)
    AEP inhibitor 7,8‐DHF <t>protect</t> <t>HUVECs</t> against oxygen–glucose deprivation by inhibiting tPA‐induced elevated LRP‐1, MMP2, and MMP9. HUVECs treated with 0.5 μM 7,8‐DHF for 24 h followed by OGD 4 h and reoxygen‐glucose plus tPA (500 ng/mL) for another 24 h as the methods part described. (A, B) Western blotting to evaluate the expression of ZO‐1, claudin5, occluding, and JAM‐1. (C) The viability of HUVECs at different time points. (D) AEP enzymatic analysis of HUVECs subjected to 24 h tPA treatment following 7,8‐DHF and OGD. (E, F) Western blotting to evaluate the expression of AEP, p‐TrkB, TrkB, LRP‐1, MMP2, and MMP9. (A) n = 4, (C) n = 6, (D) n = 4, (E) n = 4 per group. Data are presented as mean ± SEM, and statistical analysis is performed using one‐way ANOVA test followed by Tukey's multiple comparisons test when P value of Levene test > 0.05 or Welch test followed by Dunnett T3 multiple comparisons test when the P value of Levene test < 0.05. Normality and variance are assessed via Shapiro‐Wilk test and Levene's test, respectively. * P < 0.05, ** P < 0.01, *** P < 0.001.
    Complete Medium Of Huvecs (Cat No. Huvec 90011), supplied by Cyagen Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/complete medium of huvecs (cat no. huvec-90011)/product/Cyagen Biosciences
    Average 90 stars, based on 1 article reviews
    complete medium of huvecs (cat no. huvec-90011) - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    huvec complete growth medium icell–h110–001b  (iCell Gene Therapeutics)
    90
    iCell Gene Therapeutics huvec complete growth medium icell–h110–001b
    AEP inhibitor 7,8‐DHF <t>protect</t> <t>HUVECs</t> against oxygen–glucose deprivation by inhibiting tPA‐induced elevated LRP‐1, MMP2, and MMP9. HUVECs treated with 0.5 μM 7,8‐DHF for 24 h followed by OGD 4 h and reoxygen‐glucose plus tPA (500 ng/mL) for another 24 h as the methods part described. (A, B) Western blotting to evaluate the expression of ZO‐1, claudin5, occluding, and JAM‐1. (C) The viability of HUVECs at different time points. (D) AEP enzymatic analysis of HUVECs subjected to 24 h tPA treatment following 7,8‐DHF and OGD. (E, F) Western blotting to evaluate the expression of AEP, p‐TrkB, TrkB, LRP‐1, MMP2, and MMP9. (A) n = 4, (C) n = 6, (D) n = 4, (E) n = 4 per group. Data are presented as mean ± SEM, and statistical analysis is performed using one‐way ANOVA test followed by Tukey's multiple comparisons test when P value of Levene test > 0.05 or Welch test followed by Dunnett T3 multiple comparisons test when the P value of Levene test < 0.05. Normality and variance are assessed via Shapiro‐Wilk test and Levene's test, respectively. * P < 0.05, ** P < 0.01, *** P < 0.001.
    Huvec Complete Growth Medium Icell–H110–001b, supplied by iCell Gene Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/huvec complete growth medium icell–h110–001b/product/iCell Gene Therapeutics
    Average 90 stars, based on 1 article reviews
    huvec complete growth medium icell–h110–001b - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    AEP inhibitor 7,8‐DHF protect HUVECs against oxygen–glucose deprivation by inhibiting tPA‐induced elevated LRP‐1, MMP2, and MMP9. HUVECs treated with 0.5 μM 7,8‐DHF for 24 h followed by OGD 4 h and reoxygen‐glucose plus tPA (500 ng/mL) for another 24 h as the methods part described. (A, B) Western blotting to evaluate the expression of ZO‐1, claudin5, occluding, and JAM‐1. (C) The viability of HUVECs at different time points. (D) AEP enzymatic analysis of HUVECs subjected to 24 h tPA treatment following 7,8‐DHF and OGD. (E, F) Western blotting to evaluate the expression of AEP, p‐TrkB, TrkB, LRP‐1, MMP2, and MMP9. (A) n = 4, (C) n = 6, (D) n = 4, (E) n = 4 per group. Data are presented as mean ± SEM, and statistical analysis is performed using one‐way ANOVA test followed by Tukey's multiple comparisons test when P value of Levene test > 0.05 or Welch test followed by Dunnett T3 multiple comparisons test when the P value of Levene test < 0.05. Normality and variance are assessed via Shapiro‐Wilk test and Levene's test, respectively. * P < 0.05, ** P < 0.01, *** P < 0.001.

    Journal: CNS Neuroscience & Therapeutics

    Article Title: Asparagine Endopeptidase Inhibition Attenuates Tissue Plasminogen Activator‐Induced Brain Hemorrhagic Transformation After Ischemic Stroke

    doi: 10.1111/cns.70345

    Figure Lengend Snippet: AEP inhibitor 7,8‐DHF protect HUVECs against oxygen–glucose deprivation by inhibiting tPA‐induced elevated LRP‐1, MMP2, and MMP9. HUVECs treated with 0.5 μM 7,8‐DHF for 24 h followed by OGD 4 h and reoxygen‐glucose plus tPA (500 ng/mL) for another 24 h as the methods part described. (A, B) Western blotting to evaluate the expression of ZO‐1, claudin5, occluding, and JAM‐1. (C) The viability of HUVECs at different time points. (D) AEP enzymatic analysis of HUVECs subjected to 24 h tPA treatment following 7,8‐DHF and OGD. (E, F) Western blotting to evaluate the expression of AEP, p‐TrkB, TrkB, LRP‐1, MMP2, and MMP9. (A) n = 4, (C) n = 6, (D) n = 4, (E) n = 4 per group. Data are presented as mean ± SEM, and statistical analysis is performed using one‐way ANOVA test followed by Tukey's multiple comparisons test when P value of Levene test > 0.05 or Welch test followed by Dunnett T3 multiple comparisons test when the P value of Levene test < 0.05. Normality and variance are assessed via Shapiro‐Wilk test and Levene's test, respectively. * P < 0.05, ** P < 0.01, *** P < 0.001.

    Article Snippet: The HUVECs were cultured in complete culture medium for HUVEC (CM‐0122, Procell Life Science & Technology, China).

    Techniques: Western Blot, Expressing